ArticleCureus2026
When the Air Gets Thin, and the Blood Gets Thick: Choroidal Hemangioma in High-Altitude Polycythemia.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Choroidal hemangioma is a rare benign vascular tumor that can cause visual impairment due to associated subretinal fluid. Systemic factors influencing its presentation and activity are not well-understood. We report a unique case of choroidal hemangioma diagnosed in a patient who developed high-altitude polycythemia, highlighting the possible role of systemic hypoxia and blood hyperviscosity in aggravating choroidal vascular tumors. A 36-year-old male soldier, posted at an altitude of approximately 16,300 feet, presented with painless diminution of vision in the right eye. Fundus examination revealed an orange-red, elevated lesion located superior to the optic disc, approximately two disc diameters in size, with subretinal fluid extending to the fovea, suggestive of choroidal hemangioma. Hematological work-up revealed hemoglobin 18.8 g/dL and hematocrit 60.6%, consistent with high-altitude polycythemia. The serum erythropoietin level was normal, while the JAK 2 mutation and antinuclear antibody (ANA) were negative. Lipid profile demonstrated hypertriglyceridemia (525 mg/dL) and elevated very low-density lipoprotein (VLDL) (105 mg/dL). The patient underwent three sessions of therapeutic phlebotomy, following which the hemoglobin decreased to 16.6 g/dL. The patient also received a single intravitreal Eylea (aflibercept) injection, following which the subretinal fluid subsided significantly. The patient was subsequently advised to avoid future high-altitude exposure after his hematocrit normalized and visual acuity improved. Awareness of systemic contributory factors is important in the evaluation and management of choroidal vascular tumors. Choroidal hemangioma in the setting of high-altitude polycythemia is rare. Chronic hypoxia-induced hyperviscosity may contribute to vascular dilation and permeability changes within the choroid. Recognition of this association is crucial for timely diagnosis and effective management of choroidal hemangioma to preserve vision.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.